Semaglutide vs Raloxifene: side-by-side comparison
Semaglutide (GLP-1 receptor agonist) and Raloxifene (Selective estrogen receptor modulator (SERM)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Semaglutide | Raloxifene |
|---|---|---|
| Therapeutic class | GLP-1 receptor agonist | Selective estrogen receptor modulator (SERM) |
| CAS | 910463-68-2 | 84449-90-1 |
| ATC | A10BJ06 | G03XC01 |
| Molecular weight | 4113.6 g/mol | 473.59 g/mol |
| Brands with this active ingredient | 2 | 1 |
What they share
Semaglutide and Raloxifene share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Semaglutide acts by a different mechanism than Raloxifene, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Semaglutide: Semaglutide binds and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta and alpha cells, the central nervous system and the gastrointestinal tract. Raloxifene: Raloxifene binds estrogen receptors and produces tissue-selective effects: estrogen-agonist activity in bone (preserving bone mineral density) and on lipid metabolism (lowering LDL cholesterol), while exhibiting estrogen…
Indications compared
Semaglutide: Semaglutide is approved in adults with type 2 diabetes, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Raloxifene: Raloxifene is approved for prevention and treatment of postmenopausal osteoporosis, and for reduction of invasive breast cancer risk in postmenopausal women at increased risk.
Safety profile
Semaglutide: The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, usually mild to moderate and tending to attenuate over weeks. Raloxifene: Common adverse effects include hot flashes (paradoxically common because raloxifene is a partial estrogen agonist/antagonist), leg cramps and peripheral oedema.
Frequently asked questions
Is Semaglutide better than Raloxifene? ▾
Semaglutide and Raloxifene are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Semaglutide and Raloxifene be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Semaglutide
Products with Raloxifene
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.